CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 24 target
Drug / intervention
Tislelizumab +2 moredrug
Likely dose
Tislelizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06349837
NCT06349837Phase 1RecruitingOn TrackUpdated 2mo ago
CompareCT.gov

Safety and Tolerability of Low Dose Radiotherapy Plus Concurrent Partial Stereotactic Ablative Radiotherapy (Eclipse-RT) and Tislelizumab in Patients With Bulky Tumors

Sichuan University·interventional·Posted Apr 5, 2024·Updated May 1, 2026

In Brief

A Phase 1 clinical trial evaluating Tislelizumab, Low Dose Radiotherapy, and 1 other intervention for Solid Tumor. Currently recruiting, targeting 24 participants across 1 site.

Detailed Summary

This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with bulky tumors who have failed standard therapy. At least 9 participants will be enrolled in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20252026202720282029
First PostedApr 5, 2024
Enrollment StartApr 18, 2024
Primary CompletionMar 31, 2028
Study CompletionNov 30, 2028
TodayJul 1, 2026
Enrollment to primary: 4.0 yearsPosted 2.2 years agoPrimary completion in 1.8 years

Interventions

Tislelizumabdrug

Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.

Low Dose Radiotherapyradiation

LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.

Stereotactic Ablative Radiotherapyradiation

Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.